S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
Log in
NASDAQ:VNDA

Vanda Pharmaceuticals Stock Forecast, Price & News

$13.96
+0.23 (+1.68 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.66
Now: $13.96
$14.01
50-Day Range
$12.34
MA: $13.45
$14.16
52-Week Range
$7.12
Now: $13.96
$15.35
Volume603,347 shs
Average Volume429,748 shs
Market Capitalization$763.50 million
P/E Ratio38.78
Dividend YieldN/A
Beta0.56
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Vanda Pharmaceuticals logo

MarketRank

Overall MarketRank

1.66 out of 5 stars

Analyst Opinion: 2.1Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400
Employees284

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$227.19 million
Cash Flow$2.16 per share
Book Value$7.70 per share

Profitability

Net Income$115.55 million

Miscellaneous

Market Cap$763.50 million
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$13.96
+0.23 (+1.68 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

How has Vanda Pharmaceuticals' stock price been impacted by Coronavirus?

Vanda Pharmaceuticals' stock was trading at $10.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VNDA shares have increased by 31.7% and is now trading at $13.96.
View which stocks have been most impacted by COVID-19
.

Is Vanda Pharmaceuticals a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Vanda Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VNDA, but not buy additional shares or sell existing shares.
View analyst ratings for Vanda Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Vanda Pharmaceuticals?

Wall Street analysts have given Vanda Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vanda Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Vanda Pharmaceuticals
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, October, 28th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.03. The biopharmaceutical company had revenue of $60.31 million for the quarter, compared to analyst estimates of $64 million. Vanda Pharmaceuticals had a return on equity of 4.56% and a net margin of 8.02%.
View Vanda Pharmaceuticals' earnings history
.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Wednesday, October, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $240-260 million, compared to the consensus revenue estimate of $251.05 million.

What price target have analysts set for VNDA?

7 brokers have issued 12-month target prices for Vanda Pharmaceuticals' shares. Their forecasts range from $12.00 to $25.00. On average, they anticipate Vanda Pharmaceuticals' stock price to reach $15.71 in the next year. This suggests a possible upside of 12.6% from the stock's current price.
View analysts' price targets for Vanda Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Vanda Pharmaceuticals' key competitors?

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the following people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 60, Pay $1.43M)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec. (Age 44, Pay $599.18k)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 51, Pay $587.14k)
  • Mr. Kevin Patrick Moran, Acting CFO, VP & Treasurer (Age 36)
  • Mr. Aranthan Jones II, Chief Corp. Affairs & Communications Officer (Age 44)
  • Mr. Joakim Wijkstrom, Sr. VP & Chief Marketing Officer (Age 54)
  • Mr. Scott L. Howell, Chief People Officer
  • Ms. Elizabeth Van Every, Head of Corp. Affairs

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Prairiewood Capital LLC (0.11%), Exchange Traded Concepts LLC (0.10%), State of Alaska Department of Revenue (0.08%) and Wedge Capital Management L L P NC (0.02%). Company insiders that own Vanda Pharmaceuticals stock include Aranthan Jones II, Gian Piero Reverberi, James Patrick Kelly, Joakim Wijkstrom, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams.
View institutional ownership trends for Vanda Pharmaceuticals
.

Which institutional investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Aranthan Jones II, Joakim Wijkstrom, Mihael Hristos Polymeropoulos, Richard W Dugan, and Timothy Williams.
View insider buying and selling activity for Vanda Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Vanda Pharmaceuticals stock?

VNDA stock was bought by a variety of institutional investors in the last quarter, including Prairiewood Capital LLC, Wedge Capital Management L L P NC, and Exchange Traded Concepts LLC.
View insider buying and selling activity for Vanda Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $13.96.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $763.50 million and generates $227.19 million in revenue each year. The biopharmaceutical company earns $115.55 million in net income (profit) each year or $2.11 on an earnings per share basis. Vanda Pharmaceuticals employs 284 workers across the globe.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is www.vandapharma.com.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.